- Home
- MKL vs ONC Comparison
MKL vs ONC Comparison
Compare MKL & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MKL | ONC |
|---|---|---|
| Founded | 1930 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | 12000 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2B | 31.4B |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | MKL | ONC |
|---|---|---|
| Price | $1,798.50 | $294.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $2,100.00 | $385.10 |
| AVG Volume (30 Days) | 62.1K | ★ 178.0K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,513,233,000.00 | N/A |
| Revenue This Year | N/A | $723.76 |
| Revenue Next Year | $2.26 | $15.04 |
| P/E Ratio | ★ N/A | $614.06 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1,719.41 | $228.93 |
| 52 Week High | $2,207.59 | $385.22 |
Technical Indicators
Market Signals| Indicator | MKL | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 30.98 | 41.83 |
| Support Level | N/A | $283.56 |
| Resistance Level | $1,998.57 | $300.00 |
| Average True Range (ATR) | 51.22 | 6.64 |
| MACD | -18.61 | -2.11 |
| Stochastic Oscillator | 22.88 | 11.89 |
Price Performance
Historical ComparisonAbout MKL Markel Group Inc.
Markel's primary business is property and casualty insurance. The company focuses primarily on specialty lines, ranging from areas such as executive liability to commercial equine insurance. The acquisition of Alterra in 2013 added substantial reinsurance operations, which now account for a little over 10% of premiums. The company uses capital generated by its insurance operations to buy noninsurance operations in diverse areas, such as bakery equipment manufacturing and residential homebuilding.
About ONC BeiGene Ltd. American Depositary Shares
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.